Ikena Oncology, Inc. (IKNA) Stock Forecast 2025 - AI Price Prediction & Analysis

Q: What factors influence Ikena Oncology, Inc. stock price forecasts?

Our analysis considers financial metrics, sector trends, market sentiment, technical indicators, and macroeconomic factors.

Ikena Oncology, Inc. (IKNA) AI Stock Price Forecast & Investment Analysis

Latest Analysis Date: July 18, 2025 Jul 18, 2025

Ikena Oncology, Inc. (IKNA) - Comprehensive Stock Analysis & Investment Research

Company Overview & Business Profile

Ikena Oncology, Inc. (Stock Symbol: IKNA) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry. The organization employs approximately 82 professionals worldwide . The company has established itself as an emerging investment opportunity with substantial growth potential.

Financial Performance & Key Metrics Analysis

Annual Revenue: $47 million generating a -141.2% net profit margin .

Market Capitalization: $61 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -19.6% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Advanced AI Stock Prediction & Price Target Analysis

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Ikena Oncology, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Market Position & Competitive Advantage Analysis

Ikena Oncology, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities . . The company maintains a healthy 8.0% gross margin, indicating strong pricing power and operational efficiency.

Loading Ikena Oncology, Inc. interactive price chart and technical analysis...

Comprehensive Investment Metrics & Financial Analysis - Ikena Oncology, Inc. (IKNA)

Deep dive into Ikena Oncology, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Ikena Oncology, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Ikena Oncology, Inc.: With a P/E ratio of -1.27, the market sees the stock as potentially undervalued.

P/E Ratio -1.27x

P/B Ratio 0.52x

Market Cap $61M

EPS $-1.22

Book Value/Share $2.45

Revenue/Share $0.08

Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Ikena Oncology, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Ikena Oncology, Inc.: An ROE of -19.6% indicates room for improvement in shareholder value creation.

ROE -19.6%

ROA -15.8%

ROIC -19.0%

Gross Margin 8.0%

Operating Margin -157.4%

Net Margin -141.2%

EBT Margin -133.5%

Understanding Financial Health Metrics

What these metrics mean: These ratios assess Ikena Oncology, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Ikena Oncology, Inc.: A current ratio of 8.53 indicates strong liquidity.

Current Ratio 8.53x

Quick Ratio 8.38x

D/E Ratio 0.03x

Financial Leverage 1.18x

Working Capital $138M

Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Ikena Oncology, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Ikena Oncology, Inc.: Free cash flow of $-68M indicates cash challenges that need attention.

Operating Cash Flow $-67M

Free Cash Flow $-68M

Capital Spending $-1M

FCF/Sales -219.5%

CapEx/Sales 3.1%

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Ikena Oncology, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Ikena Oncology, Inc.: An asset turnover of 0.12x suggests room for improvement in asset utilization.

Asset Turnover 0.12x

Fixed Assets Turnover 3.4x

Understanding Financial Statement Data

What these metrics mean: Key figures from Ikena Oncology, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Ikena Oncology, Inc.: With annual revenue of $47M, Ikena Oncology, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)

Total Revenue $47M

Operating Income $-68M

Net Income $-59M

R&D Expense $41M

SG&A Expense $67M

Balance Sheet Highlights ($ Millions)

Total Current Assets $95M

Cash & Short-term Investments $93M

Total Liabilities $15M

Dividend & Shareholder Information

Shares Outstanding 48M

Growth Metrics (YoY)

EPS Growth -81.9%

Ikena Oncology, Inc. (IKNA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Ikena Oncology, Inc. stock analysis.

Loading Ikena Oncology, Inc. comprehensive fundamental analysis and insider trading data...

Latest Ikena Oncology, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Ikena Oncology, Inc. (IKNA) stock price and investment outlook.

IKNA Stock Quote Price and Forecast | CNN

1y ago, source: CNN

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline ...

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena ...

1mon ago, source: FOX40 News

ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis ...

Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA ... - Nasdaq

1y ago, source: Nasdaq

Ikena Oncology, Inc. (IKNA) has been on a downward spiral lately with significant selling pressure. After declining 33% over the past four weeks, the stock looks well positioned for a trend ...

Ikena Oncology Inc. Company & People | IKNA | Barron's

2y ago, source: Barron's

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline ...

Ikena Oncology, Inc.: Ikena Oncology Acquires Pionyr Immunotherapeutics ...

2y ago, source: Finanznachrichten

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif.

Here's Why Momentum in Ikena Oncology, Inc. (IKNA) Should Keep going

2y ago, source: Nasdaq

There are several stocks that passed through the screen and Ikena Oncology, Inc. (IKNA) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.

IKNA - Ikena Oncology Inc Executives | Morningstar

5mon ago, source: Morningstar

Learn about the executive team and board of directors at Ikena Oncology Inc (IKNA:XNAS) and review their bios and compensation over the latest fiscal years.

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in ...

2y ago, source: Seeking Alpha

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented initial clinical data ...

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

3y ago, source: Yahoo Finance

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Ikena Oncology, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company	Ticker Symbol	90-Day AI Forecast	Market Cap (USD M)	P/E Ratio	P/B Ratio
Acumen Pharmaceuticals, Inc.	ABOS	Unlock Forecast	$93M	-1.9x	0.8x
Abpro Holdings, Inc.	ABP	Unlock Forecast	$0M	x	0.0x
Abpro Holdings, Inc.	ABPWW	Unlock Forecast	$0M	x	0.0x
Arcellx, Inc.	ACLX	Unlock Forecast	$3725M	-74.1x	8.9x
Alpha Cognition Inc.	ACOG	Unlock Forecast	$130M	x	4.1x
Adaptimmune Therapeutics PLC	ADAP	Unlock Forecast	$91M	-13.2x	-11.8x
ADMA BIOLOGICS, INC.	ADMA	Unlock Forecast	$4374M	20.9x	11.0x
Adaptive Biotechnologies Corp	ADPT	Unlock Forecast	$1977M	-4.6x	11.0x
Adverum Biotechnologies, Inc.	ADVM	Unlock Forecast	$58M	-1.8x	2.2x
AGENUS INC	AGEN	Unlock Forecast	$136M	-0.5x	-0.5x
AIM ImmunoTech Inc.	AIM	Unlock Forecast	$2M	-0.5x	-183.3x
AIM ImmunoTech Inc.	AIMI	Unlock Forecast	$2M	x	x
Alector, Inc.	ALEC	Unlock Forecast	$255M	-1.2x	3.6x
Aligos Therapeutics, Inc.	ALGS	Unlock Forecast	$96M	-19.2x	0.9x
Allogene Therapeutics, Inc.	ALLO	Unlock Forecast	$262M	-1.4x	0.8x
Kalaris Therapeutics, Inc.	ALVR	Unlock Forecast	$49M	-0.5x	0.4x
AMGEN INC	AMGN	Unlock Forecast	$158903M	24.0x	21.4x
Apogee Therapeutics, Inc.	APGE	Unlock Forecast	$2241M	-20.5x	4.3x
Aptose Biosciences Inc.	APTO	Unlock Forecast	$6M	0.0x	-1.3x
Aptose Biosciences Inc.	APTOF	Unlock Forecast	$3M	x	x
Armata Pharmaceuticals, Inc.	ARMP	Unlock Forecast	$97M	-1.0x	-1.6x
Artiva Biotherapeutics, Inc.	ARTV	Unlock Forecast	$70M	x	0.5x
Athira Pharma, Inc.	ATHA	Unlock Forecast	$16M	-0.2x	0.5x
Atara Biotherapeutics, Inc.	ATRA	Unlock Forecast	$143M	24.7x	-1.1x
aTYR PHARMA INC	ATYR	Unlock Forecast	$515M	-3.6x	6.9x
Aura Biosciences, Inc.	AURA	Unlock Forecast	$407M	-4.9x	2.3x
Autolus Therapeutics plc	AUTL	Unlock Forecast	$466M	x	1.3x
ANAVEX LIFE SCIENCES CORP.	AVXL	Unlock Forecast	$814M	-17.3x	9.0x
BioAtla, Inc.	BCAB	Unlock Forecast	$125M	-1.1x	1.0x
BioCardia, Inc.	BCDA	Unlock Forecast	$12M	-0.6x	-7.8x
BRAINSTORM CELL THERAPEUTICS INC.	BCLI	Unlock Forecast	$7M	-4.9x	-0.9x
BIOCRYST PHARMACEUTICALS INC	BCRX	Unlock Forecast	$1802M	-12.1x	-4.0x
Black Diamond Therapeutics, Inc.	BDTX	Unlock Forecast	$168M	11.6x	1.3x
Beam Therapeutics Inc.	BEAM	Unlock Forecast	$1677M	-12.6x	1.6x
BIOGEN INC.	BIIB	Unlock Forecast	$18125M	12.8x	1.5x
Black Hawk Acquisition Corp	BKHA	Unlock Forecast	$0M	x	0.0x
Black Hawk Acquisition Corp	BKHAU	Unlock Forecast	$0M	x	0.0x
bluebird bio, Inc.	BLUE	Unlock Forecast	$49M	-0.2x	-0.8x
Cabaletta Bio, Inc.	CABA	Unlock Forecast	$148M	-1.6x	0.8x
Candel Therapeutics, Inc.	CADL	Unlock Forecast	$338M	-4.6x	4.5x
C4 Therapeutics, Inc.	CCCC	Unlock Forecast	$185M	-2.6x	1.1x
Cidara Therapeutics, Inc.	CDTX	Unlock Forecast	$728M	-1.0x	5.1x
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.	CELZ	Unlock Forecast	$8M	-3.4x	1.2x
CERO THERAPEUTICS HOLDINGS, INC.	CERO	Unlock Forecast	$3M	x	-196.2x
CERO THERAPEUTICS HOLDINGS, INC.	CEROW	Unlock Forecast	$2M	x	-0.5x
Cullinan Therapeutics, Inc.	CGEM	Unlock Forecast	$449M	-4.1x	0.8x
COMPUGEN LTD	CGEN	Unlock Forecast	$136M	x	2.7x
CG Oncology, Inc.	CGON	Unlock Forecast	$2052M	x	3.1x
COGNITION THERAPEUTICS INC	CGTX	Unlock Forecast	$183M	-0.5x	26.0x
Pelthos Therapeutics Inc.	CHRO	Unlock Forecast	$8M	x	-2.0x
Coherus Oncology, Inc.	CHRS	Unlock Forecast	$143M	0.8x	1.2x
Calidi Biotherapeutics, Inc.	CLDI	Unlock Forecast	$6M	-0.9x	3.3x
Compass Therapeutics, Inc.	CMPX	Unlock Forecast	$418M	-4.8x	4.5x
Coeptis Therapeutics Holdings, Inc.	COEPW	Unlock Forecast	$M	x	x
Caribou Biosciences, Inc.	CRBU	Unlock Forecast	$172M	-1.5x	1.0x
Cardiff Oncology, Inc.	CRDF	Unlock Forecast	$154M	-4.0x	2.6x
CARGO Therapeutics, Inc.	CRGX	Unlock Forecast	$215M	x	0.9x
CURIS INC	CRIS	Unlock Forecast	$18M	-0.3x	-2.9x
CRISPR Therapeutics AG	CRSP	Unlock Forecast	$4801M	-12.1x	2.8x
CHAMPIONS ONCOLOGY, INC.	CSBR	Unlock Forecast	$111M	-17.8x	20.4x
CEL SCI CORP	CVM	Unlock Forecast	$51M	-0.9x	7.2x
Cyclo Therapeutics, Inc.	CYTH	Unlock Forecast	$26M	-0.6x	-1.9x
Cyclo Therapeutics, Inc.	CYTHW	Unlock Forecast	$7M	x	-0.5x
DBV Technologies S.A.	DBVT	Unlock Forecast	$1479M	-3.3x	514.8x
Ginkgo Bioworks Holdings, Inc.	DNA	Unlock Forecast	$568M	-13.9x	0.3x
Denali Therapeutics Inc.	DNLI	Unlock Forecast	$2111M	-8.7x	1.9x
PRECISION BIOSCIENCES INC	DTIL	Unlock Forecast	$58M	-2.2x	1.7x
DYADIC INTERNATIONAL INC	DYAI	Unlock Forecast	$28M	-7.3x	11.4x
Editas Medicine, Inc.	EDIT	Unlock Forecast	$231M	-0.8x	3.7x
Elevation Oncology, Inc.	ELEV	Unlock Forecast	$22M	-1.0x	0.5x
ELUTIA INC.	ELUT	Unlock Forecast	$94M	-1.4x	-0.1x
enGene Holdings Inc.	ENGN	Unlock Forecast	$221M	3.7x	1.0x
enGene Holdings Inc.	ENGNW	Unlock Forecast	$37M	x	0.1x
Entera Bio Ltd.	ENTX	Unlock Forecast	$91M	8.5x	5.3x
ENZO BIOCHEM INC	ENZ	Unlock Forecast	$25M	-3.0x	0.5x
ENZO BIOCHEM INC	ENZB	Unlock Forecast	$37M	x	0.8x
Estrella Immunopharma, Inc.	ESLA	Unlock Forecast	$36M	-3.1x	-16.9x
Estrella Immunopharma, Inc.	ESLAW	Unlock Forecast	$4M	x	5.3x
EXELIXIS, INC.	EXEL	Unlock Forecast	$11059M	18.4x	5.4x
EXOZYMES INC.	EXOZ	Unlock Forecast	$78M	x	10.8x
FATE THERAPEUTICS INC	FATE	Unlock Forecast	$136M	-1.3x	0.5x
4D Molecular Therapeutics, Inc.	FDMT	Unlock Forecast	$396M	-3.0x	0.9x
FENNEC PHARMACEUTICALS INC.	FENC	Unlock Forecast	$232M	1758.3x	-39.7x
Finch Therapeutics Group, Inc.	FNCH	Unlock Forecast	$20M	-0.1x	1.4x
FutureTech II Acquisition Corp.	FTII	Unlock Forecast	$-26M	x	-0.7x
FutureTech II Acquisition Corp.	FTIIU	Unlock Forecast	$-26M	x	-0.8x
FutureTech II Acquisition Corp.	FTIIW	Unlock Forecast	$0M	x	0.0x
GILEAD SCIENCES, INC.	GILD	Unlock Forecast	$144266M	22.9x	7.3x
Monte Rosa Therapeutics, Inc.	GLUE	Unlock Forecast	$400M	16.5x	1.5x
Genenta Science S.p.A.	GNTA	Unlock Forecast	$64M	x	5.1x
Green Planet Bio Engineering Co. Ltd.	GPLB	Unlock Forecast	$M	x	x
HALOZYME THERAPEUTICS, INC.	HALO	Unlock Forecast	$9010M	16.2x	27.1x
HilleVax, Inc.	HLVX	Unlock Forecast	$103M	-0.6x	0.7x
Humacyte, Inc.	HUMA	Unlock Forecast	$247M	-3.3x	61.0x
Humacyte, Inc.	HUMAW	Unlock Forecast	$163M	x	-2.6x
ImmunityBio, Inc.	IBRX	Unlock Forecast	$2427M	-3.6x	-4.1x
Ikena Oncology, Inc.	IKNA	Unlock Forecast	$61M	-1.3x	0.5x
Inhibikase Therapeutics, Inc.	IKT	Unlock Forecast	$170M	-1.0x	2.1x
Immunocore Holdings plc	IMCR	Unlock Forecast	$1659M	x	4.3x
Immunovant, Inc.	IMVT	Unlock Forecast	$2607M	-14.5x	4.3x
IN8BIO, INC.	INAB	Unlock Forecast	$21M	-0.4x	2.4x
Inhibrx Biosciences, Inc.	INBX	Unlock Forecast	$387M	-6.8x	5.6x
MiNK Therapeutics, Inc.	INKT	Unlock Forecast	$59M	-1.5x	-1.4x
Inmune Bio, Inc.	INMB	Unlock Forecast	$64M	-2.5x	2.2x
INTENSITY THERAPEUTICS, INC.	INTS	Unlock Forecast	$8M	-2.2x	3.6x
IOVANCE BIOTHERAPEUTICS, INC.	IOVA	Unlock Forecast	$920M	-4.5x	1.3x
Century Therapeutics, Inc.	IPSC	Unlock Forecast	$47M	-0.7x	0.2x
iTeos Therapeutics, Inc.	ITOS	Unlock Forecast	$393M	-2.8x	0.7x
Invivyd, Inc.	IVVD	Unlock Forecast	$62M	-0.4x	1.5x
EXOZYMES INC.	IZTC	Unlock Forecast	$99M	x	-27.5x
Jasper Therapeutics, Inc.	JSPR	Unlock Forecast	$48M	-3.2x	2.0x
Jasper Therapeutics, Inc.	JSPRW	Unlock Forecast	$3M	x	0.0x
Kalaris Therapeutics, Inc.	KLRS	Unlock Forecast	$47M	x	0.9x
Klotho Neurosciences, Inc.	KLTO	Unlock Forecast	$39M	x	3.7x
Klotho Neurosciences, Inc.	KLTOW	Unlock Forecast	$1M	x	0.4x
Kodiak Sciences Inc.	KOD	Unlock Forecast	$539M	-2.5x	7.7x
Kiromic Biopharma, Inc.	KRBPQ	Unlock Forecast	$0M	x	x
Krystal Biotech, Inc.	KRYS	Unlock Forecast	$4487M	30.6x	4.3x
Kymera Therapeutics, Inc.	KYMR	Unlock Forecast	$3541M	-17.8x	3.7x
Kyverna Therapeutics, Inc.	KYTX	Unlock Forecast	$166M	x	0.9x
LadRx Corp	LADX	Unlock Forecast	$M	x	x
Lineage Cell Therapeutics, Inc.	LCTX	Unlock Forecast	$267M	-4.7x	5.5x
LENZ Therapeutics, Inc.	LENZ	Unlock Forecast	$1140M	-6.7x	5.5x
Liminatus Pharma, Inc.	LIMN	Unlock Forecast	$0M	x	x
Lexeo Therapeutics, Inc.	LXEO	Unlock Forecast	$265M	-0.4x	1.9x
Maze Therapeutics, Inc.	MAZE	Unlock Forecast	$592M	x	2.3x
MeiraGTx Holdings plc	MGTX	Unlock Forecast	$693M	-3.4x	20.9x
Metagenomi, Inc.	MGX	Unlock Forecast	$72M	x	0.4x
Moderna, Inc.	MRNA	Unlock Forecast	$10550M	-3.2x	1.1x
NEUROCRINE BIOSCIENCES INC	NBIX	Unlock Forecast	$13787M	39.6x	5.1x
NKGen Biotech, Inc.	NKGN	Unlock Forecast	$4M	-0.1x	-0.2x
NKGen Biotech, Inc.	NKGNW	Unlock Forecast	$1M	x	0.0x
Neumora Therapeutics, Inc.	NMRA	Unlock Forecast	$262M	-3.9x	1.4x
NOVAVAX INC	NVAX	Unlock Forecast	$1391M	3.3x	37.0x
Ocugen, Inc.	OCGN	Unlock Forecast	$298M	-4.3x	18.7x
Omega Therapeutics, Inc.	OMGA	Unlock Forecast	$9M	-0.7x	0.8x
Omega Therapeutics, Inc.	OMGAQ	Unlock Forecast	$0M	x	0.0x
VivoSim Labs, INC.	ONVO	Unlock Forecast	$35M	-0.4x	95.9x
Outlook Therapeutics, Inc.	OTLK	Unlock Forecast	$73M	-0.2x	-2.3x
PALISADE BIO, INC.	PALI	Unlock Forecast	$4M	-0.2x	0.7x
Passage BIO, Inc.	PASG	Unlock Forecast	$24M	-0.6x	0.6x
Vaxcyte, Inc.	PCVX	Unlock Forecast	$4387M	-20.4x	1.4x
BiomX Inc.	PHGE	Unlock Forecast	$15M	1.5x	0.8x
Pluri Inc.	PLUR	Unlock Forecast	$-5M	-1.4x	-9.1x
Protalix BioTherapeutics, Inc.	PLX	Unlock Forecast	$129M	20.5x	2.6x
PharmaCyte Biotech, Inc.	PMCB	Unlock Forecast	$7M	-2.6x	0.2x
Prime Medicine, Inc.	PRME	Unlock Forecast	$477M	-1.5x	7.8x
PROKIDNEY CORP.	PROK	Unlock Forecast	$-68M	x	0.0x
Poseida Therapeutics, Inc.	PSTX	Unlock Forecast	$926M	-9.6x	10.6x
Pelthos Therapeutics Inc.	PTHS	Unlock Forecast	$M	x	x
QIAGEN N.V.	QGEN	Unlock Forecast	$11177M	x	3.1x
Quince Therapeutics, Inc.	QNCX	Unlock Forecast	$87M	-1.7x	7.5x
Replimune Group, Inc.	REPL	Unlock Forecast	$932M	-3.8x	2.2x
REPLIGEN CORP	RGEN	Unlock Forecast	$6531M	8219.1x	3.3x
REGENXBIO Inc.	RGNX	Unlock Forecast	$463M	-1.8x	2.2x
Relay Therapeutics, Inc.	RLAY	Unlock Forecast	$634M	-2.0x	1.0x
Revolution Medicines, Inc.	RVMD	Unlock Forecast	$7134M	-11.1x	3.4x
Revolution Medicines, Inc.	RVMDW	Unlock Forecast	$16M	x	0.0x
RECURSION PHARMACEUTICALS, INC.	RXRX	Unlock Forecast	$2138M	-4.7x	2.3x
SAB Biotherapeutics, Inc.	SABS	Unlock Forecast	$24M	-2.3x	1.1x
SAB Biotherapeutics, Inc.	SABSW	Unlock Forecast	$0M	x	0.0x
Sana Biotechnology, Inc.	SANA	Unlock Forecast	$852M	-2.1x	7.0x
Scilex Holding Co	SCLX	Unlock Forecast	$62M	-0.4x	-0.3x
Scilex Holding Co	SCLXW	Unlock Forecast	$25M	x	-0.1x
Scinai Immunotherapeutics Ltd.	SCNI	Unlock Forecast	$5359M	-287.8x	-2577.2x
SANGAMO THERAPEUTICS, INC	SGMO	Unlock Forecast	$141M	-1.6x	7.2x
Solid Biosciences Inc.	SLDB	Unlock Forecast	$495M	-0.9x	1.7x
Silexion Therapeutics Corp	SLXN	Unlock Forecast	$4M	x	34.7x
Silexion Therapeutics Corp	SLXNW	Unlock Forecast	$866M	x	-189.1x
Senti Biosciences, Inc.	SNTI	Unlock Forecast	$51M	-1.1x	1.3x
Scholar Rock Holding Corp	SRRK	Unlock Forecast	$4069M	-18.5x	13.0x
Surrozen, Inc./DE	SRZN	Unlock Forecast	$98M	-0.5x	2.1x
Surrozen, Inc./DE	SRZNW	Unlock Forecast	$0M	x	0.0x
SUTRO BIOPHARMA, INC.	STRO	Unlock Forecast	$73M	-1.0x	-2.5x
SpringWorks Therapeutics, Inc.	SWTX	Unlock Forecast	$3539M	-9.9x	8.5x
Protara Therapeutics, Inc.	TARA	Unlock Forecast	$129M	-2.1x	0.9x
Tarsus Pharmaceuticals, Inc.	TARS	Unlock Forecast	$2417M	-12.4x	7.3x
TC BioPharm (Holdings) plc	TCBP	Unlock Forecast	$37M	x	34.5x
TC BioPharm (Holdings) plc	TCBPW	Unlock Forecast	$1M	x	1.0x
TC BioPharm (Holdings) plc	TCBPY	Unlock Forecast	$21M	x	19.1x
TScan Therapeutics, Inc.	TCRX	Unlock Forecast	$243M	-4.6x	1.4x
BIO-TECHNE Corp	TECH	Unlock Forecast	$8155M	75.2x	4.0x
Tectonic Therapeutic, Inc.	TECX	Unlock Forecast	$490M	-8.9x	1.7x
Instil Bio, Inc.	TIL	Unlock Forecast	$182M	-1.1x	1.3x
Tenaya Therapeutics, Inc.	TNYA	Unlock Forecast	$154M	-2.5x	1.5x
Tourmaline Bio, Inc.	TRML	Unlock Forecast	$600M	-3.5x	2.3x
Turnstone Biologics Corp.	TSBX	Unlock Forecast	$8M	-0.1x	0.6x
Taysha Gene Therapies, Inc.	TSHA	Unlock Forecast	$851M	-3.0x	3.4x
TITAN PHARMACEUTICALS INC	TTNP	Unlock Forecast	$8M	-0.5x	4.5x
Tevogen Bio Holdings Inc.	TVGN	Unlock Forecast	$181M	x	-29.3x
Tevogen Bio Holdings Inc.	TVGNW	Unlock Forecast	$11M	x	-1.9x
Twist Bioscience Corp	TWST	Unlock Forecast	$1720M	-12.6x	3.6x
Voyager Acquisition Corp./Cayman Islands	VACH	Unlock Forecast	$-1436M	x	0.0x
Voyager Acquisition Corp./Cayman Islands	VACHU	Unlock Forecast	$-1585M	x	0.0x
Vericel Corp	VCEL	Unlock Forecast	$1868M	262.8x	6.1x
Vigil Neuroscience, Inc.	VIGL	Unlock Forecast	$384M	-1.1x	9.3x
Vir Biotechnology, Inc.	VIR	Unlock Forecast	$636M	-2.0x	0.7x
VivoSim Labs, INC.	VIVS	Unlock Forecast	$3M	x	0.3x
Vor Biopharma Inc.	VOR	Unlock Forecast	$273M	-0.6x	3.9x
Vaxart, Inc.	VXRT	Unlock Forecast	$80M	-0.9x	2.4x
Voyager Therapeutics, Inc.	VYGR	Unlock Forecast	$201M	570.6x	0.8x
WINDTREE THERAPEUTICS INC /DE/	WINT	Unlock Forecast	$18M	-0.4x	4.2x
X4 Pharmaceuticals, Inc	XFOR	Unlock Forecast	$8M	6.4x	0.4x
Zivo Bioscience, Inc.	ZIVO	Unlock Forecast	$70M	-31.3x	-2.0x
Zura Bio Ltd	ZURA	Unlock Forecast	$131M	5.0x	0.9x

Frequently Asked Questions - Ikena Oncology, Inc. Stock Forecast

How accurate are Ikena Oncology, Inc. stock predictions?

Our AI model demonstrates 26% historical accuracy for IKNA predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Ikena Oncology, Inc. stock price forecasts?

Our analysis considers Ikena Oncology, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Ikena Oncology, Inc. a good investment in 2025?

Based on our AI analysis, Ikena Oncology, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Ikena Oncology, Inc. forecasts updated?

Ikena Oncology, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Ikena Oncology, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Ikena Oncology, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

Welcome !